Peter W. Bergum

Peter W. Bergum

Auto-generated profile, based on publicly available information

Peter W. Bergum

Corvas International, Inc., San Diego, California 92121, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PBPeter W. Bergum
Peter W. Bergum
ACAmy Cruikshank
Amy Cruikshank
SMSteven L. Maki
Steven L. Maki
CKCurtis R. Kelly
Curtis R. Kelly
WRWolfram Ruf
Wolfram Ruf
GVGeorge P. Vlasuk
George P. Vlasuk
Recombinant nematode anticoagulant protein c2 (rNAPc2) is a potent, factor Xa (fXa)-dependent small protein inhibitor of factor VIIa-tissue factor (fVIIa·TF), which binds to a site on fXa that is distinct from the catalytic center (exo-site). In the present study, the role of other fX derivatives in presenting rNAPc2 to fVIIa·TF is investigated. Catalytically active and active site blocked fXa, as well as a plasma-derived and an activation-resistant mutant of zymogen fX bound to rNAPc2 with comparable affinities (KD = 1–10 nm), and similarly supported the inhibition of fVIIa·TF (Ki * = ∼10 pm). The roles of phospholipid membrane composition in the inhibition of fVIIa·TF by rNAPc2 were investigated using TF that was either detergent-solubilized (TFS), or reconstituted into membranes, containing phosphatidylcholine (TFPC) or a mixture of phosphatidylcholine and phosphatidylserine (TFPCPS). In the absence of the fX derivative, inhibition of fVIIa·TF was similar for all three conditions (Ki ∼1 μm), whereas the addition of the fX derivative increased the respective inhibition by 35-, 150-, or 100,000-fold for TFS, TFPC, and TFPCPS. The removal of the γ-carboxyglutamic acid-containing domain from the fX derivative did not affect the binding to rNAPc2, but abolished the effect of factor Xa as a scaffold for the inhibition of fVIIa·TF by rNAPc2. The overall anticoagulant potency of rNAPc2, therefore, results from a coordinated recognition of an exo-site on fX/fXa and of the active site of fVIIa, both of which are properly positioned in the ternary fVIIa·TF·fX(a) complex assembled on an appropriate phospholipid surface.

1 May 1996 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
MCMichael Cappello
Michael Cappello
DPDavid I. Pritchard
David I. Pritchard
GVGeorge P. Vlasuk
George P. Vlasuk
BFBarbara A. Furmidge
Barbara A. Furmidge
PBPeter W. Bergum
Peter W. Bergum
SASerap Aksoy
Serap Aksoy
A potent and specific inhibitor of the human coagulation protease thrombin was identified in salivary gland extracts of the tsetse fly, Glossina morsitans morsitans, an important vector of African trypanosomiasis. This low molecular weight peptide (MW = 3,530 Da as determined by laser desorption mass spectrometry) was purified using a combination of size-exclusion chromatography and reverse-phase, high-performance liquid chromatography, respectively. Amino terminal sequencing of the purified protein reveals no homology to any previously identified serine protease inhibitor or naturally occurring anticoagulant. The tsetse thrombin inhibitor (TTI) is a stoichiometric inhibitor of thrombin, with an apparent equilibrium dissociation inhibitory constant of 584 × 10-15 M. In addition, it is also a potent inhibitor of thrombin-induced platelet aggregation. Like other hematophagous arthropods, tsetse flies appear to have evolved a novel protease inhibitor capable of antagonizing host hemostasis and facilitating blood feeding.